Effect of prorenin peptide vaccine on the early phase of diabetic retinopathy in a murine model of type 2 diabetes

Harumasa Yokota; Hiroki Hayashi; Junya Hanaguri; Satoru Yamagami; Akifumi Kushiyama; Hironori Nakagami; Taiji Nagaoka

doi:10.1371/journal.pone.0262568

. 2022 Jan 18;17(1):e0262568. doi: 10.1371/journal.pone.0262568

Effect of prorenin peptide vaccine on the early phase of diabetic retinopathy in a murine model of type 2 diabetes

Harumasa Yokota ^1,^*,^#, Hiroki Hayashi ^2,^#, Junya Hanaguri ¹, Satoru Yamagami ¹, Akifumi Kushiyama ³, Hironori Nakagami ², Taiji Nagaoka ¹

Editor: Alfred S Lewin⁴

PMCID: PMC8765632 PMID: 35041699

Abstract

Prorenin is viewed as an ideal target molecule in the prevention of diabetic retinopathy. However, no drugs are available for inhibiting activation of prorenin. Here, we tested the effect of a prorenin peptide vaccine (V_P) in the retina of a murine model of type 2 diabetes (T2D). To choose the optimal vaccine, we selected three different epitopes of the prorenin prosegment (E1, E2, and E3) and conjugated them to keyhole limpet hemocyanin (KLH). We injected C57BL/6J mice twice with KLH only (as a control vaccine), E1 conjugated with KLH (E1-KLH), E2-KLH, or E3-KLH and compared antibody titers. E2-KLH showed the highest antibody titer and specific immunoreactivity of anti-sera against prorenin, so we used E2-KLH as V_P. Then, we administered injections to the non-diabetic db/m and diabetic db/db mice, as follows: db/m + KLH, db/db + KLH, and db/db + V_P. Retinal blood flow measurement with laser speckle flowgraphy showed that the impaired retinal circulation response to both flicker light and systemic hyperoxia in db/db mice improved with V_P. Furthermore, the prolonged implicit time of b-wave and oscillatory potentials in electroretinography was prevented, and immunohistochemical analysis showed reduced microglial activation, gliosis, and vascular leakage. The enzyme-linked immunosorbent spot assay confirmed vaccinated mice had no auto-immune response against prorenin itself. The present data suggest that vaccination against prorenin is an effective and safe measure against the early pathological changes of diabetic retinopathy in T2D.

Introduction

Prorenin is the most upstream protein in the renin-angiotensin system (RAS). Until the early 2000s, prorenin was viewed as an inactive form of renin; however, the findings of two studies on prorenin published in 2003 and 2004 [1, 2] greatly changed the situation. The first study found that prorenin binds to the (pro)renin receptor via a part of the prosegment called the handle region (HR), not via the renin region [1], and the second identified the mechanism by which prorenin and the (pro)renin receptor activate the local RAS [2]. The binding of prorenin to the (pro)renin receptor leads to non-proteolytic activation of prorenin, which is followed by production of angiotensin II without conversion into mature renin, and direct activation of the receptor, which is followed by intracellular signaling by a mitogen-activated protein kinase, such as extracellular signal-regulated kinase (ERK) and p38 [3].

Levels of prorenin and (pro)renin receptor were reported to be closely correlated with the presence and severity of diabetic retinopathy [4–6]. Subsequently, a decoy peptide based on the sequence of the HR was used as a prorenin blocker and was found to have a beneficial, inhibitory effect on diabetic retinopathy by mitigating the production of vascular endothelial growth factor (VEGF) and intercellular adhesion molecule-1 (ICAM-1) [6–9]. Interestingly, some studies in diabetic rodent models showed that blocking prorenin had a more beneficial effect than inhibiting angiotensin II [7, 10], suggesting that conventional angiotensin II blockade is insufficient for preventing diabetic retinopathy. Therefore, a prorenin blocker is expected to become a new treatment for diabetic retinopathy. However, to date no prorenin blocker is available for clinical use.

Traditionally, vaccination has been used to prevent infectious diseases. Nowadays, common non-infectious diseases, such as hypertension, stroke, and Alzheimer’s disease, are becoming a target for vaccine therapy in the form of self-antigens [11–16]. After successful vaccination, the therapeutic or preventive effect can last for a long time and may have several benefits compared with conventional treatment, such as lower cost and no need for daily medication. In fact, vaccine therapy targeting angiotensin II has been extensively studied and shown to have beneficial effects, such as reducing blood pressure [17, 18], improving cardiac function [19, 20], and protecting the brain from infarction [21].

Type 2 diabetes (T2D) is highly prevalent and frequently leads to diabetic retinopathy. The peptide vaccine approach may enable us to create a new treatment for diabetic retinopathy by focusing on the pivotal role of prorenin and (pro)renin receptor in the pathogenesis of this disease. Therefore, in this study we aimed to develop a prorenin peptide vaccine by the peptide vaccine approach [11, 22]. To do so, we tested three different antigens from the prorenin prosegment to develop a prorenin peptide vaccine. Then, we assessed the efficacy of this vaccine in the retina of db/db mice as a model of T2D.

Materials and methods

Animals

One week before the experiments, we purchased the following 7-week-old male mice from Charles River Laboratories (Wilmington, MA, USA): C57BL/6J for antigen determination (n = 24), C57BL/KsJ-db/db (BKS.Cg- +Lepr^db/+Lepr^db/J) as the T2D model (n = 18), and db/m (BKS.Cg- DOCK7^m+ +Lepr^db/J) as the non-diabetic control (n = 12). The total number of mice that we currently used was fifty-four. Mice were housed in a room at a controlled temperature with a 12-hour dark/12-hour light cycle with free access to food and water. The number of animals in each group was determined to be six according to our pilot study and previous works elsewhere [15, 21]. Three mice were housed in one cage. All procedures were undertaken under systemic anesthesia with 3% isoflurane. After finishing all the procedures, animals were euthanized with CO₂ inhalation and subsequent cervical dislocation. All efforts were made to minimize suffering and maintain the environment. The animal experiments were approved by the Ethical Committee of Nihon University and performed in accordance with the tenets of the Association for Research in Vision and Ophthalmology (ARVO) and the Animal Research: Reporting of In Vivo Experiments (ARRIVE).

To minimize potential confounders such as the order of treatments and measurements, the animals were divided into a half in each group and the procedures were performed in the first half of all the groups and the last of all the groups. There was no exclusion criterion in the current experiment.

Vaccine preparation

The tertiary structure of murine prorenin (PDB ID: 5MKT) was depicted by using graphical imaging software CueMol2 (Molecular Visualization Framework; http://www.cuemol.org/) (Fig 1A). Prorenin consists of renin (white ribbons) and the prosegment (colored ribbon), which covers the enzymatic active site on renin [1]. From the 43 amino acids of prosegment, we selected three different amino acid sequences (Fig 1B): E1 (L^1PPTRTATFERIPLKKMP^17P) and E2 (T^7PFERIPLKKMP^17P), both of which contains the HR I^11PPLKK^15P, and E3 (M^16PPSVREILEER^26P), which does not contain the HR. E1, E2, and E3 were conjugated to keyhole limpet hemocyanin (KLH) [11]. For each mouse, we prepared 100 μl of peptide vaccine solution, which contained 20 μg of peptide vaccine diluted in 50 μl of normal saline and 50 μl of adjuvant, as described below. We used Freund’s complete adjuvant (Wako Pure Chemical Industries, Ltd., Osaka, Japan) in the first vaccine and Freund’s incomplete adjuvant (Wako Pure Chemical Industries, Ltd.) in the subsequent one [15, 16, 20, 21].

Fig 1 — (A) Tertiary structure of prorenin. Prorenin consists of the prosegment (blue and red) and mature renin (white). (B) Antigen E1 and E2 contained the handle region, but E3 did not. (C) Schedule for vaccination and antibody titer measurement.

Vaccination of C57BL/6 mice to determine the antigen for prorenin peptide vaccine

To determine which amino acid sequence from the prosegment elicited the best immune response, we injected C57BL/6J mice with E1 conjugated to KLH (E1-KLH), E2-KLH, and E3-KLH, as well as unconjugated KLH as a control vaccine. The first vaccination was performed at age 8 weeks and the second at age 10 weeks [15, 16, 20, 21] (Fig 1C). The injection site was the nape of the neck. Every 2 weeks until 10 weeks after the first vaccination, 10 μL of blood was collected from the tail veins. The samples were kept at -80°C until measurement of antibody titers.

Vaccination to test the effect of prorenin peptide vaccine in db/db mice as a T2D model

Diabetic db/db and non-diabetic db/m mice were randomly immunized at age 8, 10, and 17 weeks (Fig 3A), and blood sugar levels, body weight, and antibody titer were monitored every 2 weeks until 24 weeks of age. H.Y. was aware of the group allocation throughout the current experiment. Blood sugar levels were measured from the tail veins (TERUMO Co., Ltd., Tokyo, Japan). At 24 weeks of age, blood pressure was measured once by the tail-cuff method with a blood pressure monitor (THC31; Softron, Tokyo, Japan). After the measurement, all animals were euthanized and the eyeballs were extracted, as follows: sternotomy was performed under systemic anesthesia with 3% isoflurane; normal saline was perfused into the left ventricle to wash out the circulating blood, immediately followed by perfusion of 4% paraformaldehyde (PFA), and the eyeballs were enucleated. The eyeballs were kept in 4% PFA at 4°C overnight; then, after a couple of washings in phosphate-buffered saline (PBS), they were embedded in Tissue-Tek OCT Compound (Sakura Finetek Japan, Tokyo, Japan) and stored at -80°C until analysis.

Measurement of retinal blood flow

Retinal blood flow measurement was performed with a laser speckle flowgraphy (LSFG)-micro system (Softcare Co., Ltd., Fukutsu, Japan) [23]. The principle of LSFG-micro is the same as that of conventional LSFG, which has been used to non-invasively measure ocular circulation in humans with diabetic retinopathy [24, 25]. In LSFG, the blurring of the speckle pattern generated from moving blood cells is represented as the mean blur rate (MBR), which is recognized as a relative index of blood velocity. We measured the MBR on the optic nerve head (ONH) to evaluate the changes of total retinal circulation after the stimuli described below.

Induction of hyperoxia

Systemic hyperoxia was induced by inhalation of 100% oxygen for 10 minutes, as described in our previous study [23]. Briefly, the mean of three flow measurements obtained at 1-minute intervals for 3 minutes served as the baseline value before initiation of hyperoxia. Retinal blood flow was measured every minute for a total of 20 minutes, i.e., during the 10-minute inhalation (hyperoxia) and for 10 minutes afterwards (normoxia).

Flicker light stimulation

The frequency of flicker light stimulation was set at 12 Hz on the basis of our recent results [23]. Before induction of flicker stimuli, ambient light was reduced to 1 lux or less. The mice were dark-adapted for 2 hours, and the light intensity for flicker light stimulation was set at 30 lux for the rod-dominant mouse retina. Before initiating flicker light stimulation, the mean of three measurements obtained at 20-second intervals over 1 minute was calculated as the baseline value. Then, retinal blood flow was measured at 20-second intervals during 3 minutes’ flicker stimulation and for 3 minutes thereafter.

Electroretinogram in db/db mice

Mice were dark-adapted for at least 6 hours before an electroretinogram (ERG) was performed. For ERG, the mice were transferred to a room with dim red light. The pupils were dilated with 0.4% tropicamide and a full-field ERG was recorded with PuREC (Mayo Corporation, Inazawa, Japan) under inhalation anesthesia (2% isoflurane). A ground electrode was placed at the tail, and a reference electrode was put in the mouth. Corneal electrodes were attached to the surface of the cornea. To gain the maximum response of both cones and rods, 3.0 candela.s/m² of flash was used. The implicit times of the a- and b-waves were automatically measured by identifying the maximum negative and positive peaks of the trace of the ERG. The measurement was repeated three times, and the mean value was calculated. Oscillatory potentials (OPs) were isolated by setting the high-pass digital filter at 75 Hz. We selected OP1, OP2, and OP3 and calculated the total sum of the OPs (ΣOPs).

Antibody titer measurement

Enzyme-linked immunosorbent assay (ELISA) was performed to measure the antibody titer after vaccination [15, 16, 20, 21]. Briefly, a 96-well plate was coated with bovine serum albumin (BSA)-conjugated epitope (Peptide Institute Inc., Ibaraki, Japan) at 10 μg/mL and incubated overnight at 4^°C. On the next day, to avoid non-specific binding, the plate was blocked for at least 2 hours with 5% skim milk in PBS containing 0.05% Tween 20. Diluted sera (from 10- to 32,500-fold) were applied to the wells and incubated overnight at 4^°C. Each well was washed with PBS containing 0.05% Tween 20 and incubated with horseradish peroxidase-conjugated anti-mouse IgG antibody (GE Healthcare, Chicago, IL, USA) for at least 3 hours at room temperature. After washing, wells were incubated with the chromogenic substrate 3,3’-5,5’-tetramethyl benzidine (Sigma-Aldrich, St. Louis, MO, USA) for 30 minutes. Absorbance at 450 nm was measured with a microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA) after color development was stopped by 0.5 N sulfuric acid. The antibody titer of each sample was determined from the serum dilution that showed half the maximum absorbance of the plate reader by using GraphPad Prism 6 software (GraphPad Software, Inc., La Jolla, CA, USA).

ELISA for measurement of prorenin plus renin and angiotensin I

The concentration of prorenin plus renin and angiotensin I in blood was measured by using an ELISA kit for prorenin plus renin (Lifespan Biosciences, Inc., Seattle, WA, USA) and for angiotensin I (SPI-Bio, Montigny Le Bretonneux, France). All procedures were performed according to the manufacturer’s instructions.

Western blotting

One microgram of recombinant prorenin (AnaSpec, Inc., Fremont, CA, USA) and renin (AnaSpec, Inc.) and 2 μg of BSA-conjugated E2 antigen were electrophoresed by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and blotted onto polyvinylidene difluoride membrane (Millipore, Bedford, MA, USA). The blotted membranes were incubated with sera from mice immunized with E2-KLH or KLH or with commercially available anti-prorenin/renin antibody (dilution, 1:500; LifeSpan BioSciences, Inc.). After subsequent incubation with horseradish peroxidase-conjugated secondary antibody, immunoreactivity was detected with the enhanced chemiluminescence system (GE Healthcare).

Immunohistochemistry

Ten micrometer-thick sections were made with a cryostat (HM505, Microm, Walldorf, Germany). The sections were stained with isolectin B4 (IB4) (dilution, 1:400; Thermo Fisher Scientific, Waltham, MA, USA) and rabbit polyclonal antibody against (pro)renin receptor (dilution, 1:200; Sigma-Aldrich, St. Louis, MO, USA), glial fibrillary acidic protein (GFAP; ready to use, Dako, Glostrup, Denmark), ionized calcium-binding adapter molecule 1 (iba-1; dilution, 1:200; Wako Pure Chemical Industries Ltd., Osaka, Japan), and vascular endothelial growth factor (VEGF; 1:100, Sigma-Aldrich) overnight at 4°C and then incubated with secondary donkey anti-rabbit IgG (H+L) Alexa Fluor 488 (dilution, 1:400; Thermo Fisher Scientific) for 2 hours at room temperature. Albumin was immunohistochemically stained with the primary antibody (dilution, 1:200; Abcam, Cambridge, MA, USA) and incubated with an Alexa Fluor 594-conjugated anti-sheep IgG antibody (dilution, 1:400; Thermo Fisher Scientific). Immunofluorescent images were obtained by a FluoView 1000 confocal microscope (Olympus, Tokyo, Japan) and BZ-9000 microscope (Keyence, Osaka, Japan). To examine the expression of phosphorylated extracellular signal-regulated kinase (p-ERK) in the retina, the sections were stained overnight at 4°C with p-ERK (dilution, 1:100). Immunostaining was developed with a Histofine Simple Stain PO (M) Kit (Nichirei, Tokyo, Japan) in accordance with the instruction manual.

Enzyme-linked immunosorbent spot assay

Enzyme-linked immunosorbent spot (ELISPOT) assay was performed as previously described [15, 16]. Briefly, 96 well plates with polyvinylidene fluoride (PVDF) (Millipore) were coated with interleukin 4 (IL-4) or interferon-gamma (IFN-γ) capture antibodies (R&D Systems, Minneapolis, MN, USA) overnight at 4^°C. On the next day, splenocytes were extracted from control mice or immunized mice with prorenin vaccine by using two doses of Freund’s adjuvant (first dose, Freund’s adjuvant complete; second dose, Freund’s adjuvant incomplete; Sigma-Aldrich) and were incubated with recombinant mouse prorenin 1 μg/ml (Abcam), KLH 10 μg/ml (ENZO Life Sciences, Farmingdale, NY, USA), or phorbol myristate acetate (PMA) 0.1 μg/ml and ionomycin 0.1 μg/ml (Sigma-Aldrich) at 37^°C for 45 hours. After incubation with streptavidin-alkaline phosphatase, spots were developed by 5-Bromo-4-chloro-3’ indolylphosphate p-toluidine salt (BCIP) and nitro blue tetrazolium chloride (NBT) (R&D Systems). The spots were counted with a microscope (BZ-X810, Keyence).

Statistical analysis

The results are presented as means ± standard error (SE). The data were analyzed with Ekuseru-Toukei 2010 (Social Survey Research Information Co., Ltd., Tokyo, Japan). Differences between groups were analyzed by an unpaired t test. Multiple comparison analysis was performed by one-way ANOVA followed by post hoc analysis (Tukey’s test). A P value less than 0.05 was considered statistically significant.

Results

Determination of the antigen for developing a prorenin peptide vaccine

At 2 weeks postimmunization, the antibody titer was significantly increased in the E1-KLH and E2-KLH groups, but not in the E3-KLH group. The titer reached the maximum level at 4 weeks postimmunization (Fig 2A). The antibody titer of E2-KLH remained significantly higher than that of E1-KLH until 10 weeks postimmunization. To evaluate the specific reactivity of prorenin peptide vaccine with the full length of prorenin, we performed immunoblotting analysis by using sera obtained from the mice immunized with E2-KLH (Fig 2B). These sera bound to recombinant murine prorenin and BSA-conjugated E2 but not to recombinant renin. Anti-prorenin/renin antibody clearly showed blotting bands in both recombinant prorenin and renin but not in BSA-conjugated E2. Therefore, E2 was determined to be the best antigen for use as a prorenin peptide vaccine (V_P) in the current study and was used in the subsequent experiments.

Fig 2 — (A) Antibody titer in mice inoculated with E1 conjugated to KLH(E1-KLH), E2-KLH, E3-KLH, or KLH (unconjugated KLH as control) (n = 6 in each) (mean ± SE) measured by ELISA. *p < 0.05 vs E1. (B) Confirmation of specific binding of E2 to prorenin. Sera were collected from mice inoculated with E2-KLH or KLH. A commercially available anti-prorenin/renin antibody was used as a positive control. BSA, bovine serum albumin; ELISA, enzyme-linked immunosorbent assay; KLH, keyhole limpet hemocyanin; MW, molecular weight; Rec-p, recombinant prorenin; Rec-r, recombinant renin.

Antibody titer, body weight, blood glucose, blood pressure, renin activity, and (pro)renin receptor expression in db/m and db/db mice after injection of V_P

Immunization was performed in 8-, 10-, and 17-week-old db/db and db/m mice, as shown in Fig 3A. V_P successfully raised the antibody titer in db/db mice (Fig 3B) but, compared with KLH, did not affect body weight or blood glucose levels of db/db mice (Fig 3C and 3D). Because the RAS plays a crucial role in maintaining blood pressure, we measured blood pressure once at age 24 weeks (Fig 3E); neither systolic nor diastolic blood pressure showed a difference between any of the groups. To examine the effect of V_P on the concentration of prorenin and renin activity (renin and activated prorenin), we measured the serum concentration of prorenin plus renin and angiotensin I (Fig 3F): The concentration of prorenin plus renin was significantly higher in db/db + KLH (control vaccine) than in db/m + KLH and significantly lower in db/db + V_P than in db/db + KLH. The angiotensin I concentration was significantly higher in db/db + KLH and db/db + V_P than in db/m + KLH but was not different between db/db + KLH and db/db + V_P. In addition, immunohistochemical analysis showed no obvious difference between the groups in the expression of (pro)renin receptor in the retina.

Protective effect of V_P on glial function (retinal blood flow response to systemic hyperoxia and flicker light stimulation)

Systemic hyperoxia-induced decrease of retinal blood flow was confirmed in non-diabetic db/m + KLH, as previously reported [23]. In db/db + KLH, retinal blood flow was significantly increased. In contrast, in db/db + V_P, the response of retinal blood to hyperoxia was almost comparable to that in db/m + KLH. To further clarify the effect of V_P on retinal blood flow response to stimuli, we used flicker stimulation (Fig 4B). Flicker light stimulation was reported to induce a gradual increase of retinal blood flow to meet tissue demand [23], and we observed an increase of retinal blood flow in db/m + KLH. However, retinal blood flow showed an abnormal response in db/db + KLH in that it gradually decreased compared with baseline. In db/db + V_P, retinal blood flow response to flicker light stimulation gradually increased, similar to the normal response seen in db/m + KLH. Immunohistochemical analysis showed that V_P ameliorated T2D-induced overexpression of GFAP (Fig 5A and 5B) and decreased the number of iba-1–positive microglia (Fig 5C and 5D).

Fig 4 — (A) Effect of V_P on retinal blood flow response to hyperoxia stimulation at 12 weeks of age. (B) Effect of V_P on retinal blood flow response to flicker light stimulation at 14 weeks of age. KLH, keyhole limpet hemocyanin; V_P, prorenin peptide vaccine. *p < 0.05, **p < 0.01 vs. db/m + KLH, ^†p < 0.05, ^††p < 0.01 vs. db/db + KLH, NS = not significant. N = 6 in each group.

Fig 5 — (A) and (B) Gliosis was evaluated by immunofluorescence of glial fibrillary acidic protein (GFAP) at 24 weeks of age. (C) and (D) Microglia activation was quantified by ionized calcium-binding adapter molecule 1-positive cells at 24 weeks of age. DAPI, 4′,6-diamidino-2-phenylindole; GCL, ganglion cell layer; GFAP, glial fibrillary acidic protein; iba-1, ionized calcium-binding adapter molecule 1; INL, inner nuclear layer; KLH, keyhole limpet hemocyanin; ONL, outer nuclear layer; V_P, prorenin peptide vaccine. Scale bar = 100 μm. **p < 0.01. N = 6 in each group except for GFAP expression.

Protective effect of V_P on retinal neuronal function in db/db mice

Representative ERG traces are shown in Fig 6A. We found no significant difference in the amplitude or implicit time of the a-wave between the groups (Fig 6B) or in the amplitude of the b-wave (Fig 5C); however, the implicit time of the b-wave was significantly prolonged in db/db + KLH compared with db/m + KLH. In db/db + V_P, the implicit time of the b-wave was almost normal, i.e., comparable to that in db/m + KLH (Fig 6C). To further evaluate the neuronal function of the inner layers of the retina after vaccination, we compared OPs between the groups (Fig 6D). Although we found no difference in the amplitude of ΣOPs, the implicit time of ΣOPs was significantly longer in db/db + KLH than in db/m + KLH but was significantly shorter in db/db + V_P than in db/db + KLH (Fig 6E). In addition, db/m mice were immunized with V_P, which increased the antibody titer, as assessed by ELISA (S1 Fig). We found no prolongation of the implicit time of b-wave or ΣOPs in db/m + V_P mice (S1 Fig). Immunohistochemical analysis of stress-induced mitogen-activated protein kinase expression showed a pronounced reduction of phosphorylated ERK in db/db + V_P (Fig 6F).

Inhibitory effect of V_P on VEGF expression and vascular permeability

To further clarify the beneficial effect of V_P on the pathogenesis of diabetic retinopathy, we performed immunohistochemical analysis to investigate whether V_P ameliorates hyperpermeability in the retina of the T2D murine model. As shown in Fig 7, V_P decreased the expression of VEGF and leakage of albumin in the retina of db/db + V_P mice.

Fig 7 — (A) Vascular endothelial growth factor (VEGF; green), and albumin (red) for vascular leakage in the retina. (B) Quantification of VEGF expression and albumin in the retina. **p < 0.01. DAPI, 4′,6-diamidino-2-phenylindole; GCL, ganglion cell layer; iba-1, ionized calcium-binding adapter molecule 1; INL, inner nuclear layer; KLH, keyhole limpet hemocyanin; ONL, outer nuclear layer; VEGF, vascular endothelial growth factor; V_P, prorenin peptide vaccine. Scale bar = 100 μm.

T-cell activation after inoculation with V_P

To overcome concerns about the development of unfavorable autoimmune disorders related to vaccination, ELISPOT assay was performed with splenocytes isolated from E2-immunized mice. Stimulation with KLH significantly increased the number of IL-4 spots in the splenocytes (Fig 8A) and also the number of IFN-γ spots (Fig 8B). Neither the IL-4 spots nor the IFN-γ spots were increased by stimulation with prorenin recombinant. IgG subclass assay demonstrated that IgG1/IgG2a ratio was greater than 1.0 in db/m and db/db mice (S2 Fig). These data suggest that V_P immunization activated T helper 2 (Th2) responses to induce antibody production and that intrinsic prorenin does not induce autoimmune activation.

Fig 8 — The production of interleukin 4 (A) and interferon-gamma (B) was detected as black spots. The bar graphs show the number of spots per membrane. Control is the age-matched C57BL/6 mouse without vaccination. KLH, keyhole limpet hemocyanin; IFN-γ, interferon-gamma; IL-4, interleukin 4; V_P, prorenin peptide vaccine. **p < 0.01.

Comparison of V_P with angiotensin II peptide vaccine (V_A)

To further elucidate the benefits of V_P in the prevention of diabetic retinopathy, we studied the effects of angiotensin II peptide vaccine (V_A) in this diabetic model in the same manner as V_P. As shown in Fig 9A, V_A led to an increase in the antibody titer; the increase was similar to that shown in previous reports [21]. The representative ERG traces are shown in Fig 9B. The implicit time of the b-wave and ΣOPs were significantly prolonged in db/db + V_A compared with db/db + V_P (Fig 9C).

Fig 9 — (A) Antibody titer (mean ± SE) in db/db + V_A mice. (B) Representative electroretinogram traces in db/db + V_P (green line) and db/db + V_A (blue line). (C) Implicit time of b-wave and total sum of the oscillatory potentials in db/db + V_P and db/db + V_A. ΣOPs, total sum of the oscillatory potentials; ELISA, enzyme-linked immunosorbent assay; OD50%, optical density at half-maximal binding; V_A, angiotensin II peptide vaccine; V_P, prorenin peptide vaccine. *p < 0.05, **p < 0.01.

Discussion

In this study, we found that the HR is a crucial sequence for designing a prorenin peptide vaccine. Prorenin peptide vaccine successfully protected the function of Müller glia and neurons in the retina of the T2D model. Moreover, the vaccine prevented T2D-induced microglial activation and hyperpermeability of the retina. To our knowledge, this is the first study to demonstrate that vaccination may be an alternative approach to prevent new onset of diabetic retinopathy.

Prorenin consists of renin and the prosegment. The HR is a 5-amino acid sequence located in a 43-amino acid sequence of the prosegment [1]. Because binding of the HR to the (pro)renin receptor is the rate-limiting step of proteolytic activation of prorenin [1], decoy peptides were used as prorenin blockers, such as NH2-R^10P ILLKKMPSV^19P-COOH in rats [2] and NH2-I^11P PLKKMPS^18P-COOH in mice [7, 26]. In the present study, for unknown reasons E3 (M^16PPSVREILEER^26P) did not raise an antibody titer. Taken together, findings indicate that the HR (I^11PPLKK^15P) is a key sequence for creating a peptide vaccine against prorenin that efficiently inhibits the binding of prorenin to the (pro)renin receptor. In the present study, we aimed to design a vaccine that did not affect renin because of the crucial role in the RAS, and we confirmed that the vaccine-derived antibody specifically bound to recombinant prorenin but not to renin. The angiotensin I concentration, which is mainly dependent on renin activity, was not different between KLH and prorenin peptide vaccine. This result also indicates that the antibody does not interfere with renin activity in the circulation. Renin is a rate-limiting molecule in the generation of angiotensin II in the circulatory RAS [27]. Angiotensin II plays central roles in the physiological control of systemic blood pressure and sodium balance [28]. Hence, the prorenin peptide vaccine created in the current study will not affect the physical role of renin and will independently prevent tissue damage attributed to prorenin-activated RAS.

In the present study, we used db/db mice as a murine model of T2D. During the study, the body weight of the db/db mice steadily increased up to almost double that of the non-diabetic C57BL/6J mice. The amount of vaccine injected into each mouse was identical, despite their different body weights. In humans, a study found that the immune response of obese and diabetic individuals to vaccination was compromised compared with that of non-obese, non-diabetic individuals [29]. However, throughout the 16-week period of our study, the antibody titer of the overweight db/db mice remained almost comparable to that of the lean, non-diabetic C57BL/6 mice. The abovementioned study, which investigated whether obesity affects the antibody titer after influenza vaccine, clearly demonstrated that 12-month postvaccination titers were drastically lower in people with obesity [29]. In addition, a leptin-deficient, obese mouse (ob/ob) model was reported to show a significant decrease in the number of B cells in the bone marrow [30]. Thus, a further study is needed to longitudinally observe the postvaccination titer for more than 12 months in various models of T2D with obesity.

Because a vaccine affects the whole body, safety is prioritized when considering the clinical application. In the present study, the mice did not show any signs of severe side effects that led to differences in the size and weight of the control vaccine and prorenin peptide vaccine groups. Previously, the (pro)renin receptor was reported to be involved in impaired insulin sensitivity [31]. Our current study indicates that vaccination against prorenin does not improve blood glucose levels in T2D. For the first time, the present study found higher levels of prorenin in the circulation of T2D db/db mice. Furthermore, the study suggested that prorenin peptide vaccine does not affect the circulatory RAS, as mentioned above. Taken together, our results indicate that the antibody produced in response to prorenin peptide vaccine prevents prorenin from binding to the (pro)renin receptor but does not affect the circulatory RAS.

Recent studies have paid much attention to Müller glia by focusing on early pathological changes in the retina in T2D. Studies thereby showed that observing the retinal blood flow response to both systemic hyperoxia and flicker light stimulation is useful for examining glial function [32, 33]. Systemic hyperoxia induces vasoconstriction via a biophysiological effect of endothelin-1 released from glia [32]. In contrast, to meet the oxygen and nutrient demands of neurons, flicker light stimulation induces vasodilation via nitric oxide, which is mainly produced in glia [33]. The present study showed for the first time that T2D severely affects the retinal blood flow response to hyperoxia and flicker light stimulation. Although the mechanism by which dysregulation of neurovascular coupling occurs in the retina in T2D is not fully understood, microglia may play a critical role [34]. Microglial activation is also one of the early events in the retina soon after T2D develops [35]. Prorenin was reported to directly activate cultured microglia, even when they were preincubated with an angiotensin II type 1 receptor blocker [36, 37], indicating that angiotensin II blockade is not sufficient to suppress microglial activation in diabetic retinopathy. We speculate that the antibody produced by vaccination against prorenin ameliorates microglial activation and subsequently reduces the expression of pro-inflammatory cytokines in the retina in T2D. Our data demonstrate for the first time that the cascade of prorenin-(pro)renin receptor activation was involved in glial dysfunction in the early pathogenesis of diabetic retinopathy.

Neurodegenerative change has come to be recognized as one of the early features of diabetic retinopathy [38–40]. In our ERG analysis, we found no significant reduction of the amplitudes of the a-wave, b-wave, or OPs in db/db diabetic mice; these findings are in contrast with a previous study [41]. However, in our study, the implicit time of the b-wave and OPs was significantly prolonged in the db/db diabetic mice. The reason for this discrepancy is unclear, but our data clearly showed the protective effect of prorenin peptide vaccine on the neuronal retina of diabetic mice. The effect of prorenin inhibition on the neurological function of the retina was not well defined, but a study with decoy prorenin inhibitor showed that, surprisingly, the decoy peptide resulted in a further worsening of neuronal function of the retina, as demonstrated by ERG and immunohistochemical analysis of p-ERK [42]. The authors of the study speculated that by binding to the (pro)renin receptor the decoy peptide may have subsequently stimulated intracellular signaling just beneath the receptor. On the other hand, the antibody produced by the current prorenin peptide vaccine is expected to prevent prorenin from binding to the (pro)renin receptor by covering the binding site located in the prosegment. In fact, the implicit time of b-wave and ΣOPs in non-diabetic db/m mice showed no difference between KLH and prorenin peptide vaccine (S1 Fig), indicating that prorenin peptide does not have any detrimental effect on neuronal function even in non-diabetic individuals. Taken together, the prorenin peptide vaccine was found to be safer and more effective in treating diabetic retinopathy than a peptide-based prorenin inhibitor.

In addition, binding of prorenin to the (pro)renin receptor leads to overexpression of VEGF in the retina of diabetic rodents independently of the angiotensin II pathway [7]. Thus, the current results also substantiate the beneficial effect of prorenin peptide vaccine in preventing the hyperpermeability that results in edema. In patients with T2D, diabetic macular edema severely affects central vision and is one of the major concerns in treating diabetic retinopathy. Therefore, prorenin peptide vaccine is expected to become an alternative or adjuvant therapy to anti-VEGF therapy in macular edema.

In 2003, a clinical trial of a vaccine for Alzheimer’s disease was stopped because of a severe adverse effect, i.e., 3% of the participants experienced T cell-mediated aseptic meningoencephalitis [43]. Therefore, safety issues need to be carefully considered before taking the prorenin vaccine to the next step. The current ELISPOT assay clearly demonstrated that T-cells of the vaccine-immunized mice did not show an auto-immune response against prorenin. Furthermore, IgG subclass assay showed that the humoral immune response was significantly greater than the cellular immune response (S2 Fig). These results suggest that prorenin peptide vaccine is unlikely to cause prorenin-related autoimmune diseases.

Many studies have demonstrated beneficial protective effects of vaccination against angiotensin II in models of hypertension and brain ischemia. Moreover, angiotensin II has been suggested to be involved in the development of diabetic retinopathy [44–46]. In the present study, we administered three doses of angiotensin II peptide vaccine to db/db mice in the same manner as prorenin peptide vaccine. The antibody titer of angiotensin II peptide vaccine was almost the same as the one found in a previous study [21]. However, angiotensin II peptide vaccine did not exhibit a protective effect, at least on neuronal function of the retina in T2D. Taken together, our data indicate that, in terms of vaccine therapy for diabetic retinopathy, prorenin is more suitable as a target molecule than angiotensin II.

The present study has several limitations. First, we did not determine the actual retinal levels of prorenin in the db/db mice. To our knowledge, no study has investigated the expression levels of prorenin in the retina of db/db mice. Besides the retina, one study clearly showed that mRNA levels of prorenin were increased in the kidney of db/db mice and that a decoy peptide suppressed the pathogenesis of diabetic nephropathy [26]. Another group reported that a decoy peptide successfully inhibited the effect of increased prorenin in streptozotocin-induced type 1 diabetes rodent model [7]. To further clarify whether prorenin peptide vaccine shows a beneficial effect locally or systemically, a future study needs to examine the expression and alteration of prorenin and angiotensin II in db/db mice with or without vaccination. Second, the mechanism by which prorenin peptide vaccine protects retinal neurovascular coupling and neuronal function in T2D is not yet determined. Prorenin was reported to be capable of activating microglia via the (pro)renin receptor, and chronic inflammation has been reported to take place prior to neuronal and vascular injuries [39, 47]. However, controversy remains regarding the involvement of the angiotensin II type 1 receptor. Some studies showed that conventional angiotensin II blockade inhibits microglial activation [48–51], but others found that angiotensin II is unnecessary for prorenin-induced activation of microglia [36, 52]. Presumably, microglia can be activated by either pathway. Third, we have not yet determined where the produced antibody is located in the db/db diabetic retina, i.e., whether the antibody remains within the blood vessels or leaks out of the blood vessels. To resolve this issue, we need to use a larger diabetic animal model, such as a pig, which will allow us to collect a large enough ocular sample [53] to determine the intraocular levels of the antibody.

Conclusion

The current findings suggest that a prorenin peptide vaccine may be effective in preventing diabetic retinopathy by suppressing microglial activation, gliosis, neuronal dysfunction and hyperpermeability in T2D. When preparing a prorenin peptide vaccine, the HR must be included in the antigen sequence. To bring this technique to the next level, efforts must be made to establish a consensus about the efficacy and safety of peptide vaccine therapy for retinal diseases.

Supporting information

S1 Fig. The results of prorenin peptide vaccine (V_P) injection in non-diabetic db/m mice.

(A) Antibody titer of db/m mice immunized with V_P. (B) Electroretinography at 20 weeks of age in db/m mice immunized with keyhole limpet hemocyanin (KLH) control vaccine (db/m + KLH) and V_P (db/m + V_P). (C) Implicit time of b-wave and total sum of the oscillatory potentials in db/m + KLH and db/m + V_P. ΣOPs, total sum of the oscillatory potentials; ELISA, enzyme-linked immunosorbent assay; KLH, keyhole limpet hemocyanin; OD50%, optical density at half-maximal binding; V_P, prorenin peptide vaccine.

(TIF)

Click here for additional data file.^{(246.8KB, tif)}

S2 Fig. IgG subclass analysis of the antibody of prorenin in db/m and db/db mice immunized with prorenin peptide vaccine.

Horseradish peroxidase-conjugated anti-mouse IgG1, IgG2a, IgG2b, and IgG2c (Abcam, Cambridge, MA, USA) were used to determine the IgG subclasses. The IgG1/IgG2a ratio was greater than 1.0, showing that activated T helper 2 cells (Th2) predominated over T helper 1 cells (Th1) in both db/m and db/db mice.

(TIF)

Click here for additional data file.^{(68.1KB, tif)}

S1 Raw image

(TIF)

Click here for additional data file.^{(3MB, tif)}

S2 Raw image

(TIFF)

Click here for additional data file.^{(3MB, tiff)}

S3 Raw image

(TIFF)

Click here for additional data file.^{(3MB, tiff)}

Acknowledgments

We thank Akiko Tomioka and Yuka Yanagida for technical support.

Data Availability

All relevant data are within the manuscript.

Funding Statement

This research was funded by the Ministry of Education, Culture, Sports, Science and Technology of Japan (grant numbers 18H06266 and 20K09835 [to H.Y.]).

References

1.Suzuki F, Hayakawa M, Nakagawa T, Nasir UM, Ebihara A, Iwasawa A, et al. Human prorenin has "gate and handle" regions for its non-proteolytic activation. The Journal of biological chemistry. 2003;278(25):22217–22. Epub 2003/04/10. doi: 10.1074/jbc.M302579200 . [DOI] [PubMed] [Google Scholar]
2.Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the “handle” region for nonproteolytic activation of prorenin. Journal of Clinical Investigation. 2004;114(8):1128–35. doi: 10.1172/jci21398 [DOI] [PMC free article] [PubMed] [Google Scholar]
3.Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. The Journal of clinical investigation. 2002;109(11):1417–27. Epub 2002/06/05. doi: 10.1172/JCI14276 ; PubMed Central PMCID: PMC150992. [DOI] [PMC free article] [PubMed] [Google Scholar]
4.Yokota H, Mori F, Kai K, Nagaoka T, Izumi N, Takahashi A, et al. Serum prorenin levels and diabetic retinopathy in type 2 diabetes: new method to measure serum level of prorenin using antibody activating direct kinetic assay. The British journal of ophthalmology. 2005;89(7):871–3. Epub 2005/06/21. doi: 10.1136/bjo.2004.056580 ; PubMed Central PMCID: PMC1772730. [DOI] [PMC free article] [PubMed] [Google Scholar]
5.Kawazu S, Minagawa S, Yazawa M, Tsuchida A, Ihara C, Hosaka D, et al. Sex difference and possible relationship to microvascular complications of serum prorenin levels in type 2 diabetic patients, measured by a novel antibody-activating direct enzyme kinetic assay. Journal of diabetes and its complications. 2004;18(5):275–81. Epub 2004/09/01. doi: 10.1016/j.jdiacomp.2004.03.001 . [DOI] [PubMed] [Google Scholar]
6.Kanda A, Noda K, Saito W, Ishida S. (Pro)renin receptor is associated with angiogenic activity in proliferative diabetic retinopathy. Diabetologia. 2012;55(11):3104–13. Epub 2012/08/30. doi: 10.1007/s00125-012-2702-2 . [DOI] [PubMed] [Google Scholar]
7.Satofuka S, Ichihara A, Nagai N, Noda K, Ozawa Y, Fukamizu A, et al. (Pro)renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation. Diabetes. 2009;58(7):1625–33. Epub 2009/04/25. doi: 10.2337/db08-0254 ; PubMed Central PMCID: PMC2699867. [DOI] [PMC free article] [PubMed] [Google Scholar]
8.Kanda A, Ishida S. (Pro)renin receptor: Involvement in diabetic retinopathy and development of molecular targeted therapy. Journal of diabetes investigation. 2018. doi: 10.1111/jdi.12842 [DOI] [PMC free article] [PubMed] [Google Scholar]
9.Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. The Journal of clinical investigation. 2004;114(8):1128–35. Epub 2004/10/19. doi: 10.1172/JCI21398 ; PubMed Central PMCID: PMC522242. [DOI] [PMC free article] [PubMed] [Google Scholar]
10.Ichihara A, Suzuki F, Nakagawa T, Kaneshiro Y, Takemitsu T, Sakoda M, et al. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. Journal of the American Society of Nephrology: JASN. 2006;17(7):1950–61. Epub 2006/06/02. doi: 10.1681/ASN.2006010029 . [DOI] [PubMed] [Google Scholar]
11.Nakagami H, Koriyama H, Morishita R. Peptide Vaccines for Hypertension and Diabetes Mellitus. Vaccines (Basel). 2014;2(4):832–40. doi: 10.3390/vaccines2040832 ; PubMed Central PMCID: PMC4494253. [DOI] [PMC free article] [PubMed] [Google Scholar]
12.Cornforth AN, Fowler AW, Carbonell DJ, Dillman RO. Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival. Cancer Immunol Immunother. 2011;60(1):123–31. Epub 2010/10/21. doi: 10.1007/s00262-010-0925-y . [DOI] [PMC free article] [PubMed] [Google Scholar]
13.Schenk D. Amyloid-beta immunotherapy for Alzheimer’s disease: the end of the beginning. Nat Rev Neurosci. 2002;3(10):824–8. Epub 2002/10/03. doi: 10.1038/nrn938 . [DOI] [PubMed] [Google Scholar]
14.Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature. 2000;408(6815):982–5. Epub 2001/01/05. doi: 10.1038/35050116 . [DOI] [PubMed] [Google Scholar]
15.Pang Z, Nakagami H, Osako MK, Koriyama H, Nakagami F, Tomioka H, et al. Therapeutic vaccine against DPP4 improves glucose metabolism in mice. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(13):E1256–63. doi: 10.1073/pnas.1322009111 ; PubMed Central PMCID: PMC3977240. [DOI] [PMC free article] [PubMed] [Google Scholar]
16.Kawakami R, Nozato Y, Nakagami H, Ikeda Y, Shimamura M, Yoshida S, et al. Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/kexin type 9 (PCSK9) epitope in mice. PloS one. 2018;13(2):e0191895. doi: 10.1371/journal.pone.0191895 ; PubMed Central PMCID: PMC5811007. [DOI] [PMC free article] [PubMed] [Google Scholar]
17.Nakagami F, Koriyama H, Nakagami H, Osako MK, Shimamura M, Kyutoku M, et al. Decrease in blood pressure and regression of cardiovascular complications by angiotensin II vaccine in mice. PloS one. 2013;8(3):e60493. doi: 10.1371/journal.pone.0060493 ; PubMed Central PMCID: PMC3609829. [DOI] [PMC free article] [PubMed] [Google Scholar]
18.Koriyama H, Nakagami H, Nakagami F, Osako MK, Kyutoku M, Shimamura M, et al. Long-Term Reduction of High Blood Pressure by Angiotensin II DNA Vaccine in Spontaneously Hypertensive Rats. Hypertension. 2015;66(1):167–74. doi: 10.1161/HYPERTENSIONAHA.114.04534 . [DOI] [PubMed] [Google Scholar]
19.Pan Y, Zhou Z, Zhang H, Zhou Y, Li Y, Li C, et al. The ATRQbeta-001 vaccine improves cardiac function and prevents postinfarction cardiac remodeling in mice. Hypertension research: official journal of the Japanese Society of Hypertension. 2019;42(3):329–40. Epub 2018/12/28. doi: 10.1038/s41440-018-0185-3 . [DOI] [PubMed] [Google Scholar]
20.Watanabe R, Suzuki JI, Wakayama K, Maejima Y, Shimamura M, Koriyama H, et al. A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction. Scientific reports. 2017;7:43920. doi: 10.1038/srep43920 ; PubMed Central PMCID: PMC5339733. [DOI] [PMC free article] [PubMed] [Google Scholar]
21.Wakayama K, Shimamura M, Suzuki JI, Watanabe R, Koriyama H, Akazawa H, et al. Angiotensin II Peptide Vaccine Protects Ischemic Brain Through Reducing Oxidative Stress. Stroke; a journal of cerebral circulation. 2017;48(5):1362–8. doi: 10.1161/STROKEAHA.116.016269 . [DOI] [PubMed] [Google Scholar]
22.Nakagami H, Koriyama H, Morishita R. Therapeutic vaccines for hypertension and dyslipidemia. International heart journal. 2014;55(2):96–100. doi: 10.1536/ihj.13-383 . [DOI] [PubMed] [Google Scholar]
23.Hanaguri J, Yokota H, Watanabe M, Kuo L, Yamagami S, Nagaoka T. Longitudinal stability of retinal blood flow regulation in response to flicker stimulation and systemic hyperoxia in mice assessed with laser speckle flowgraphy. Scientific reports. 2020;10(1):19796. Epub 2020/11/15. doi: 10.1038/s41598-020-75296-y ; PubMed Central PMCID: PMC7666208. [DOI] [PMC free article] [PubMed] [Google Scholar]
24.Iwase T, Kobayashi M, Yamamoto K, Ra E, Terasaki H. Effects of photocoagulation on ocular blood flow in patients with severe non-proliferative diabetic retinopathy. PloS one. 2017;12(3):e0174427. Epub 2017/03/30. doi: 10.1371/journal.pone.0174427 ; PubMed Central PMCID: PMC5371365. [DOI] [PMC free article] [PubMed] [Google Scholar]
25.Toto L, Evangelista F, Viggiano P, Erroi E, D’Onofrio G, Libertini D, et al. Changes in Ocular Blood Flow after Ranibizumab Intravitreal Injection for Diabetic Macular Edema Measured Using Laser Speckle Flowgraphy. BioMed research international. 2020;2020:9496242. Epub 2020/02/28. doi: 10.1155/2020/9496242 ; PubMed Central PMCID: PMC7035512. [DOI] [PMC free article] [PubMed] [Google Scholar]
26.Ichihara A, Sakoda M, Kurauchi-Mito A, Nishiyama A, Itoh H. Involvement of receptor-bound prorenin in development of nephropathy in diabetic db/db mice. Journal of the American Society of Hypertension: JASH. 2008;2(5):332–40. Epub 2008/09/01. doi: 10.1016/j.jash.2008.04.009 . [DOI] [PubMed] [Google Scholar]
27.Ichihara A, Sakoda M, Kurauchi-Mito A, Narita T, Kinouchi K, Bokuda K, et al. New approaches to blockade of the renin-angiotensin-aldosterone system: characteristics and usefulness of the direct renin inhibitor aliskiren. Journal of pharmacological sciences. 2010;113(4):296–300. Epub 2010/08/03. doi: 10.1254/jphs.10r04fm . [DOI] [PubMed] [Google Scholar]
28.Titze J, Luft FC. Speculations on salt and the genesis of arterial hypertension. Kidney international. 2017;91(6):1324–35. Epub 2017/05/16. doi: 10.1016/j.kint.2017.02.034 . [DOI] [PubMed] [Google Scholar]
29.Sheridan PA, Paich HA, Handy J, Karlsson EA, Hudgens MG, Sammon AB, et al. Obesity is associated with impaired immune response to influenza vaccination in humans. Int J Obes (Lond). 2012;36(8):1072–7. Epub 2011/10/26. doi: 10.1038/ijo.2011.208 ; PubMed Central PMCID: PMC3270113. [DOI] [PMC free article] [PubMed] [Google Scholar]
30.Claycombe K, King LE, Fraker PJ. A role for leptin in sustaining lymphopoiesis and myelopoiesis. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(6):2017–21. Epub 2008/02/06. doi: 10.1073/pnas.0712053105 ; PubMed Central PMCID: PMC2538874. [DOI] [PMC free article] [PubMed] [Google Scholar]
31.Shamansurova Z, Tan P, Ahmed B, Pepin E, Seda O, Lavoie JL. Adipose tissue (P)RR regulates insulin sensitivity, fat mass and body weight. Mol Metab. 2016;5(10):959–69. doi: 10.1016/j.molmet.2016.08.009 ; PubMed Central PMCID: PMC5034688. [DOI] [PMC free article] [PubMed] [Google Scholar]
32.Song Y, Nagaoka T, Yoshioka T, Ono S, Wada T, Nakabayashi S, et al. Glial Endothelin-1 Regulates Retinal Blood Flow During Hyperoxia in Cats. Investigative ophthalmology & visual science. 2016;57(11):4962–9. Epub 2016/09/23. doi: 10.1167/iovs.16-19599 . [DOI] [PubMed] [Google Scholar]
33.Yoshioka T, Nagaoka T, Song Y, Yokota H, Tani T, Yoshida A. Role of neuronal nitric oxide synthase in regulating retinal blood flow during flicker-induced hyperemia in cats. Investigative ophthalmology & visual science. 2015;56(5):3113–20. Epub 2015/03/19. doi: 10.1167/iovs.14-15854 . [DOI] [PubMed] [Google Scholar]
34.Phipps JA, Dixon MA, Jobling AI, Wang AY, Greferath U, Vessey KA, et al. The renin-angiotensin system and the retinal neurovascular unit: A role in vascular regulation and disease. Experimental eye research. 2019;187:107753. Epub 2019/08/14. doi: 10.1016/j.exer.2019.107753 . [DOI] [PubMed] [Google Scholar]
35.Arroba AI, Alcalde-Estevez E, Garcia-Ramirez M, Cazzoni D, de la Villa P, Sanchez-Fernandez EM, et al. Modulation of microglia polarization dynamics during diabetic retinopathy in db/db mice. Biochimica et biophysica acta. 2016;1862(9):1663–74. Epub 2016/06/09. doi: 10.1016/j.bbadis.2016.05.024 . [DOI] [PubMed] [Google Scholar]
36.Shi P, Grobe JL, Desland FA, Zhou G, Shen XZ, Shan Z, et al. Direct pro-inflammatory effects of prorenin on microglia. PloS one. 2014;9(10):e92937. doi: 10.1371/journal.pone.0092937 ; PubMed Central PMCID: PMC4193744. [DOI] [PMC free article] [PubMed] [Google Scholar]
37.McCarthy CA, Widdop RE, Deliyanti D, Wilkinson-Berka JL. Brain and retinal microglia in health and disease: An unrecognized target of the renin-angiotensin system. Clinical and experimental pharmacology & physiology. 2013;40(8):571–9. Epub 2013/04/23. doi: 10.1111/1440-1681.12099 . [DOI] [PubMed] [Google Scholar]
38.Kern TS, Barber AJ. Retinal ganglion cells in diabetes. The Journal of physiology. 2008;586(Pt 18):4401–8. doi: 10.1113/jphysiol.2008.156695 ; PubMed Central PMCID: PMC2614025. [DOI] [PMC free article] [PubMed] [Google Scholar]
39.Vujosevic S, Muraca A, Alkabes M, Villani E, Cavarzeran F, Rossetti L, et al. Early Microvascular and Neural Changes in Patients with Type 1 and Type 2 Diabetes Mellitus without Clinical Signs of Diabetic Retinopathy. Retina. 2019;39(3):435–45. doi: 10.1097/IAE.0000000000001990 . [DOI] [PubMed] [Google Scholar]
40.Sohn EH, van Dijk HW, Jiao C, Kok PH, Jeong W, Demirkaya N, et al. Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus. Proceedings of the National Academy of Sciences of the United States of America. 2016;113(19):E2655–64. doi: 10.1073/pnas.1522014113 ; PubMed Central PMCID: PMC4868487. [DOI] [PMC free article] [PubMed] [Google Scholar]
41.Bogdanov P, Corraliza L, Villena JA, Carvalho AR, Garcia-Arumi J, Ramos D, et al. The db/db mouse: a useful model for the study of diabetic retinal neurodegeneration. PloS one. 2014;9(5):e97302. doi: 10.1371/journal.pone.0097302 ; PubMed Central PMCID: PMC4023966. [DOI] [PMC free article] [PubMed] [Google Scholar]
42.Wilkinson-Berka JL, Heine R, Tan G, Cooper ME, Hatzopoulos KM, Fletcher EL, et al. RILLKKMPSV influences the vasculature, neurons and glia, and (pro)renin receptor expression in the retina. Hypertension. 2010;55(6):1454–60. Epub 2010/04/07. doi: 10.1161/HYPERTENSIONAHA.109.148221 . [DOI] [PubMed] [Google Scholar]
43.Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61(1):46–54. Epub 2003/07/09. doi: 10.1212/01.wnl.0000073623.84147.a8 . [DOI] [PubMed] [Google Scholar]
44.Horio N, Clermont AC, Abiko A, Abiko T, Shoelson BD, Bursell SE, et al. Angiotensin AT(1) receptor antagonism normalizes retinal blood flow and acetylcholine-induced vasodilatation in normotensive diabetic rats. Diabetologia. 2004;47(1):113–23. Epub 2003/11/18. doi: 10.1007/s00125-003-1262-x . [DOI] [PubMed] [Google Scholar]
45.Mori F, Hikichi T, Nagaoka T, Takahashi J, Kitaya N, Yoshida A. Inhibitory effect of losartan, an AT1 angiotensin II receptor antagonist, on increased leucocyte entrapment in retinal microcirculation of diabetic rats. The British journal of ophthalmology. 2002;86(10):1172–4. Epub 2002/09/18. doi: 10.1136/bjo.86.10.1172 ; PubMed Central PMCID: PMC1771309. [DOI] [PMC free article] [PubMed] [Google Scholar]
46.Otani A, Takagi H, Oh H, Suzuma K, Matsumura M, Ikeda E, et al. Angiotensin II-stimulated vascular endothelial growth factor expression in bovine retinal pericytes. Investigative ophthalmology & visual science. 2000;41(5):1192–9. Epub 2001/02/07. . [PubMed] [Google Scholar]
47.Zeng Y, Cao D, Yu H, Yang D, Zhuang X, Hu Y, et al. Early retinal neurovascular impairment in patients with diabetes without clinically detectable retinopathy. The British journal of ophthalmology. 2019. doi: 10.1136/bjophthalmol-2018-313582 [DOI] [PubMed] [Google Scholar]
48.Saavedra JM. Angiotensin II AT(1) receptor blockers ameliorate inflammatory stress: a beneficial effect for the treatment of brain disorders. Cellular and molecular neurobiology. 2012;32(5):667–81. Epub 2011/09/23. doi: 10.1007/s10571-011-9754-6 ; PubMed Central PMCID: PMC3302944. [DOI] [PMC free article] [PubMed] [Google Scholar]
49.Dong YF, Kataoka K, Tokutomi Y, Nako H, Nakamura T, Toyama K, et al. Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer’s disease. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2011;25(9):2911–20. Epub 2011/05/20. doi: 10.1096/fj.11-182873 . [DOI] [PubMed] [Google Scholar]
50.Benicky J, Sanchez-Lemus E, Honda M, Pang T, Orecna M, Wang J, et al. Angiotensin II AT1 receptor blockade ameliorates brain inflammation. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. 2011;36(4):857–70. Epub 2010/12/15. doi: 10.1038/npp.2010.225 ; PubMed Central PMCID: PMC3055735. [DOI] [PMC free article] [PubMed] [Google Scholar]
51.Miyoshi M, Miyano K, Moriyama N, Taniguchi M, Watanabe T. Angiotensin type 1 receptor antagonist inhibits lipopolysaccharide-induced stimulation of rat microglial cells by suppressing nuclear factor kappaB and activator protein-1 activation. The European journal of neuroscience. 2008;27(2):343–51. Epub 2008/01/15. doi: 10.1111/j.1460-9568.2007.06014.x . [DOI] [PubMed] [Google Scholar]
52.Zhu T, Miller AG, Deliyanti D, Berka DR, Agrotis A, Campbell DJ, et al. Prorenin stimulates a pro-angiogenic and pro-inflammatory response in retinal endothelial cells and an M1 phenotype in retinal microglia. Clinical and experimental pharmacology & physiology. 2015;42(5):537–48. doi: 10.1111/1440-1681.12376 . [DOI] [PubMed] [Google Scholar]
53.Renner S, Blutke A, Clauss S, Deeg CA, Kemter E, Merkus D, et al. Porcine models for studying complications and organ crosstalk in diabetes mellitus. Cell and tissue research. 2020;380(2):341–78. Epub 2020/01/15. doi: 10.1007/s00441-019-03158-9 . [DOI] [PubMed] [Google Scholar]

PLoS One. doi: 10.1371/journal.pone.0262568.r001

Decision Letter 0

Alfred S Lewin

25 Jun 2021

PONE-D-21-16317

Effect of prorenin peptide vaccine on the early phase of diabetic retinopathy in a murine model of type 2 diabetes

PLOS ONE

Dear Dr. Yokota,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please quantify your results for Figs. 3-6. Please evaluate the T cell response to immunization. Please add a control group for your in vivo efficacy study of the peptide vaccine.

Please submit your revised manuscript by Aug 09 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Alfred S Lewin, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. As part of your revisions, please provide additional details pertaining to your animal research procedures. Please revise your Methods to address the following points: (1) sample size: how many animals per group and how did you determine the numbers (power analysis? pilot study? previously published data/findings?); (2) provide complete information about all methods undertaken to minimize pain and distress of the animals in your work, including method of euthanasia which is not currently specified. (3) Please discuss your monitoring parameters (physical and behavioral signs to assess health and well-being), in addition to your humane endpoints (criteria used to determine when to euthanize animals in cases where animals become sick/moribund). (4) Please state the rate of mortality for animals who died unexpectedly (and state cause(s) of death). (6) Please also discuss supportive care that you provided to the animals. (7) Lastly, please complete and submit the ARRIVE Guidelines checklist (Essential 10) with your revision: https://arriveguidelines.org/resources/author-checklists

3. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The manuscript titled “Effect of prorenin peptide vaccine on the early phase of diabetic retinopathy in a murine model of type 2 diabetes” by Yokota et al. tested vaccines using three epitopes from the prosegment of prorenin conjugated to keyhole limpet hemocyanin (KLH), evaluated the efficacy of one of them in diabetic retina using db/db mice, and showed protective effects against the early pathological changes of diabetic retinopathy in this model. While this study is interesting and maybe significant, there are some major concerns as listed below.

• While authors showed that E2-KLH conjugate had highest anti-prorenin antibody titer, this peptide is 11 amino acid long and could potentially activate autoreactive T-cells. T-cell response should be evaluated. IgG subclass of peptide-induced antibodies and levels of complement system proteins should also be investigated.

• The experimental design for in vivo efficacy study of the peptide vaccine lacked the db/m + Vp treated control group.

• In all figures with immunostaining, there are no quantitative measurements and statistical analysis (Fig 3H, Fig 4C, Fig 5F, Fig 6).

• As elevated prorenin in the retina is thought to contribute pathogenesis of diabetic retinopathy, the levels of prorenin/renin and Ang I/II in the retina with and without treatments should be measured. This is important as authors showed that this peptide vaccine seemed to only block prorenin-induced pathway(s) independent of Ang II, without affecting circulating renin level and it is important to know whether the beneficial effects of this peptide vaccine is mediated via systemic effects or locally via blocking prorenin and its receptor activation. It would be also interesting to compare the efficacy of the prorenin peptide vaccine with classic RAS blockers such as ACE inhibitors and Ang II receptor blockers.

• In the Introduction and Discussion, there is insufficient discussion on related background literature, why prorenin is an ideal target molecule in the prevention of diabetic retinopathy, some important early reports on prorenin in diabetic retinopathy are not mentioned. There is insufficient discussion on data presented and potential mechanisms.

Reviewer #2: Yokota et al. “Effect of prorenin peptide vaccine on the early phase of diabetic retinopathy in a

murine model of type 2 diabetes”

This is an interesting manuscript because it demonstrates that vaccination may be an alternative approach to prevent diabetic retinopathy. Furthermore, the authors report that T2D severely affects the retinal blood flow response to hyperoxia and flicker light stimulation. Moreover, the efficacy of the prorenin-directed vaccine indicates that prorenin contributes to glial dysfunction and early pathogenesis of diabetic retinopathy. Finally, they speculate that microglial activation may compromise neurovascular coupling and thereby promote retinopathy.

Specific Points

1. While the text states that there is no difference in the prorenin receptor level, Fig 3H shows that there is less in the retinal from the vaccinated animal. Please quantify the results shown in Fig 3H.

2. Please modify Fig 4A and B to indicate the times at which there are statistically significant differences between the experimental groups.

3. Please quantify the results shown in Fig 4C.

4. Please quantify the results shown in Fig 5F.

5. Please quantify the results shown in Fig 6.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Jan 18;17(1):e0262568. doi: 10.1371/journal.pone.0262568.r002

Author response to Decision Letter 0

3 Dec 2021

We thank all the reviewers for providing constructive comments and valuable suggestions for the manuscript. The reviewer’s comments are addressed point-by-point below.

Responses to Reviewer 1

Comment 1: The manuscript titled “Effect of prorenin peptide vaccine on the early phase of diabetic retinopathy in a murine model of type 2 diabetes” by Yokota et al. tested vaccines using three epitopes from the prosegment of prorenin conjugated to keyhole limpet hemocyanin (KLH), evaluated the efficacy of one of them in diabetic retina using db/db mice, and showed protective effects against the early pathological changes of diabetic retinopathy in this model. While this study is interesting and maybe significant, there are some major concerns as listed below.

Response 1: Thank you very much for your positive remarks and useful suggestions. We have provided point-by-point responses to each of your comments below.

Comment 2: While authors showed that E2-KLH conjugate had highest anti-prorenin antibody titer, this peptide is 11 amino acid long and could potentially activate autoreactive T-cells. T-cell response should be evaluated. IgG subclass of peptide-induced antibodies and levels of complement system proteins should also be investigated.

Response 2: We very much appreciate your comment, especially from the view of safety concerns. As you point out, we evaluated whether the antigen peptide (E2) itself activates T-cells in vaccinated mice, as assessed by the ELISPOT assay. As shown in the new Figure 8, KLH treatment induced IFN- γ expression, but prorenin recombinant treatment did not, suggesting that E2 peptide does not include the T-cell epitope and therefore does not activate T cells. We also evaluated the IgG subclass of vaccine-induced antibody, and the results suggested that Th2 (mouse IgG1) is dominant (Supplementary Figure 2). Because mouse IgG1 does not have Fc-dependent action, we speculate that the induced antibody does not activate the complement pathway. We have added new text at lines 205-217 in the Methods, lines 285-293 in the Results, and lines 386-393 in the Discussion.

Comment 3: The experimental design for in vivo efficacy study of the peptide vaccine lacked the db/m + Vp treated control group.

Response 3: Thank you so much for your suggestion. Actually, we performed ERG also in db/m + VP. The reason why we excluded the ERG data of db/m + VP in the first submission was that we have not yet performed the flicker and high O2 tests. When we performed these tests in our previous work (Hanaguri et al, Sci Rep 2021), we found it almost impossible to perform all these procedures in this series. Therefore, we decided to keep the tests that we performed in the three groups to a minimum to efficiently prove the efficacy of prorenin peptide vaccine. In the current version of the manuscript, we have added only the ERG data of the implicit times of the b-wave and ΣOPs in db/m + VP compared with db/m + KLH, as shown in Supplementary Figure 1. The experimental design for db/m + VP is provided as Supplementary Material 1, and the results are presented in lines 274-277.

Comment 4: In all figures with immunostaining, there are no quantitative measurements and statistical analysis (Fig 3H, Fig 4C, Fig 5F, Fig 6).

Response 4: Thank you so much for your suggestion. We now show the quantitative measurements and results of the statistical analysis of the intensity of immunofluorescence for each staining except for DAB staining for p-ERK; we are unable to show the analysis for p-ERK staining because we could not detect sufficient fluorescein staining to enable us to quantitate the amount of p-ERK in the retina. If we want to quantitate p-ERK in the retina in a future study, we will need to prepare the whole retina sample for Western blotting.

Comment 5: As elevated prorenin in the retina is thought to contribute pathogenesis of diabetic retinopathy, the levels of prorenin/renin and Ang I/II in the retina with and without treatments should be measured. This is important as authors showed that this peptide vaccine seemed to only block prorenin-induced pathway(s) independent of Ang II, without affecting circulating renin level and it is important to know whether the beneficial effects of this peptide vaccine is mediated via systemic effects or locally via blocking prorenin and its receptor activation. It would be also interesting to compare the efficacy of the prorenin peptide vaccine with classic RAS blockers such as ACE inhibitors and Ang II receptor blockers.

Response 5: We completely agree with your suggestion. As mentioned in the limitations, we did not show the retinal levels of prorenin in diabetic db/db mice. In fact, in the current study we attempted to perform an immunohistochemical analysis for prorenin and (pro)renin receptor, but we obtained results only for immunohistochemistry of the (pro)renin receptor. An alternative way to detect prorenin in the retina is PCR. Therefore, we have added a sentence to the limitations that mentions the need for a future study that uses PCR to directly demonstrate the expression of prorenin in the retina of this type 2 diabetic model (lines 409-411).

To study the effect of prorenin peptide vaccine by angiotensin II blockade, we used angiotensin II peptide vaccine (VA) instead of either conventional angiotensin II receptor blockers or angiotensin II converting enzyme inhibitors. We used this approach because we were focusing on the benefits of peptide vaccine therapy, such as low cost and, unlike the situation with daily medication, lack of concerns about patient adherence. We now present the ERG and antibody titer data in the new Figure 9. Surprisingly, angiotensin II peptide vaccine showed absolutely no protective effect even though the antibody titer was almost the same as that we found in our previous work, which showed an anti-hypertensive effect and organ protection in various models. Therefore, at least from these results, we can conclude that in terms of peptide vaccine for diabetic retinopathy, prorenin is a more suitable target molecule than angiotensin II. We have added the VA results at lines 294-300 in the Results and lines 394-402 in the Discussion. As mentioned in the limitations, we did not show the local expression of prorenin and angiotensin II in the retina of diabetic db/db mice.

Comment 6: In the Introduction and Discussion, there is insufficient discussion on related background literature, why prorenin is an ideal target molecule in the prevention of diabetic retinopathy, some important early reports on prorenin in diabetic retinopathy are not mentioned. There is insufficient discussion on data presented and potential mechanisms.

Response 6: Thank you for your suggestion. To make it easier for readers to understand why the ideal target molecule is prorenin and not angiotensin II, we have added sentences at lines 60-64 in the Introduction. In the Discussion, we have cited previous works that demonstrate a significant role of prorenin in microglial activation (lines 415-422).

Please note that during the revision process, we needed to make further minor changes; these changes are highlighted in yellow.

Responses to Reviewer 2

Comment 1: This is an interesting manuscript because it demonstrates that vaccination may be an alternative approach to prevent diabetic retinopathy. Furthermore, the authors report that T2D severely affects the retinal blood flow response to hyperoxia and flicker light stimulation. Moreover, the efficacy of the prorenin-directed vaccine indicates that prorenin contributes to glial dysfunction and early pathogenesis of diabetic retinopathy. Finally, they speculate that microglial activation may compromise neurovascular coupling and thereby promote retinopathy.

Response 1: Thank you very much for your positive remarks. We have carefully followed your suggestions, as described below.

Comment 2: While the text states that there is no difference in the prorenin receptor level, Fig 3H shows that there is less in the retinal from the vaccinated animal. Please quantify the results shown in Fig 3H.

Response 2: Thank you so much for this suggestion. We have quantified the fluorescence intensity and changed the images as well.

Comment 3: Please modify Fig 4A and B to indicate the times at which there are statistically significant differences between the experimental groups.

Response 3: Thank you for this suggestion. The difference between db/m + KLH and db/db + KLH was significant, and significance is now indicated in the figure with asterisks. In addition, the difference between db/db + KLH and db/db + VP also was significant, and this significance is indicated with daggers.

Comment 4: Please quantify the results shown in Fig 4C.

Comment 5: Please quantify the results shown in Fig 5F.

Comment 6: Please quantify the results shown in Fig 6.

Response 4, 5, 6: Thank you so much for these suggestions. We have quantified the intensity of immunofluorescence in all these figures.

Attachment

Submitted filename: Point-by-point response to reviewers 103021.docx

Click here for additional data file.^{(20.1KB, docx)}

PLoS One. doi: 10.1371/journal.pone.0262568.r003

Decision Letter 1

Alfred S Lewin

30 Dec 2021

Effect of prorenin peptide vaccine on the early phase of diabetic retinopathy in a murine model of type 2 diabetes

PONE-D-21-16317R1

Dear Dr. Yokota,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Alfred S Lewin, Ph.D.

Section Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #2: (No Response)

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: (No Response)

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

Reviewer #2: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

Reviewer #2: (No Response)

**********

6. Review Comments to the Author

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

PLoS One. doi: 10.1371/journal.pone.0262568.r004

Acceptance letter

Alfred S Lewin

7 Jan 2022

PONE-D-21-16317R1

Effect of prorenin peptide vaccine on the early phase of diabetic retinopathy in a murine model of type 2 diabetes

Dear Dr. Yokota:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Alfred S Lewin

Section Editor

PLOS ONE

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

S1 Fig. The results of prorenin peptide vaccine (V_P) injection in non-diabetic db/m mice.

(TIF)

Click here for additional data file.^{(246.8KB, tif)}

S2 Fig. IgG subclass analysis of the antibody of prorenin in db/m and db/db mice immunized with prorenin peptide vaccine.

(TIF)

Click here for additional data file.^{(68.1KB, tif)}

S1 Raw image

(TIF)

Click here for additional data file.^{(3MB, tif)}

S2 Raw image

(TIFF)

Click here for additional data file.^{(3MB, tiff)}

S3 Raw image

(TIFF)

Click here for additional data file.^{(3MB, tiff)}

Attachment

Submitted filename: Point-by-point response to reviewers 103021.docx

Click here for additional data file.^{(20.1KB, docx)}

Data Availability Statement

All relevant data are within the manuscript.

[pone.0262568.ref001] 1.Suzuki F, Hayakawa M, Nakagawa T, Nasir UM, Ebihara A, Iwasawa A, et al. Human prorenin has "gate and handle" regions for its non-proteolytic activation. The Journal of biological chemistry. 2003;278(25):22217–22. Epub 2003/04/10. doi: 10.1074/jbc.M302579200 . [DOI] [PubMed] [Google Scholar]

[pone.0262568.ref002] 2.Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the “handle” region for nonproteolytic activation of prorenin. Journal of Clinical Investigation. 2004;114(8):1128–35. doi: 10.1172/jci21398 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0262568.ref003] 3.Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. The Journal of clinical investigation. 2002;109(11):1417–27. Epub 2002/06/05. doi: 10.1172/JCI14276 ; PubMed Central PMCID: PMC150992. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0262568.ref004] 4.Yokota H, Mori F, Kai K, Nagaoka T, Izumi N, Takahashi A, et al. Serum prorenin levels and diabetic retinopathy in type 2 diabetes: new method to measure serum level of prorenin using antibody activating direct kinetic assay. The British journal of ophthalmology. 2005;89(7):871–3. Epub 2005/06/21. doi: 10.1136/bjo.2004.056580 ; PubMed Central PMCID: PMC1772730. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0262568.ref005] 5.Kawazu S, Minagawa S, Yazawa M, Tsuchida A, Ihara C, Hosaka D, et al. Sex difference and possible relationship to microvascular complications of serum prorenin levels in type 2 diabetic patients, measured by a novel antibody-activating direct enzyme kinetic assay. Journal of diabetes and its complications. 2004;18(5):275–81. Epub 2004/09/01. doi: 10.1016/j.jdiacomp.2004.03.001 . [DOI] [PubMed] [Google Scholar]

[pone.0262568.ref006] 6.Kanda A, Noda K, Saito W, Ishida S. (Pro)renin receptor is associated with angiogenic activity in proliferative diabetic retinopathy. Diabetologia. 2012;55(11):3104–13. Epub 2012/08/30. doi: 10.1007/s00125-012-2702-2 . [DOI] [PubMed] [Google Scholar]

[pone.0262568.ref007] 7.Satofuka S, Ichihara A, Nagai N, Noda K, Ozawa Y, Fukamizu A, et al. (Pro)renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation. Diabetes. 2009;58(7):1625–33. Epub 2009/04/25. doi: 10.2337/db08-0254 ; PubMed Central PMCID: PMC2699867. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0262568.ref008] 8.Kanda A, Ishida S. (Pro)renin receptor: Involvement in diabetic retinopathy and development of molecular targeted therapy. Journal of diabetes investigation. 2018. doi: 10.1111/jdi.12842 [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0262568.ref009] 9.Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. The Journal of clinical investigation. 2004;114(8):1128–35. Epub 2004/10/19. doi: 10.1172/JCI21398 ; PubMed Central PMCID: PMC522242. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0262568.ref010] 10.Ichihara A, Suzuki F, Nakagawa T, Kaneshiro Y, Takemitsu T, Sakoda M, et al. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. Journal of the American Society of Nephrology: JASN. 2006;17(7):1950–61. Epub 2006/06/02. doi: 10.1681/ASN.2006010029 . [DOI] [PubMed] [Google Scholar]

[pone.0262568.ref011] 11.Nakagami H, Koriyama H, Morishita R. Peptide Vaccines for Hypertension and Diabetes Mellitus. Vaccines (Basel). 2014;2(4):832–40. doi: 10.3390/vaccines2040832 ; PubMed Central PMCID: PMC4494253. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0262568.ref012] 12.Cornforth AN, Fowler AW, Carbonell DJ, Dillman RO. Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival. Cancer Immunol Immunother. 2011;60(1):123–31. Epub 2010/10/21. doi: 10.1007/s00262-010-0925-y . [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0262568.ref013] 13.Schenk D. Amyloid-beta immunotherapy for Alzheimer’s disease: the end of the beginning. Nat Rev Neurosci. 2002;3(10):824–8. Epub 2002/10/03. doi: 10.1038/nrn938 . [DOI] [PubMed] [Google Scholar]

[pone.0262568.ref014] 14.Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature. 2000;408(6815):982–5. Epub 2001/01/05. doi: 10.1038/35050116 . [DOI] [PubMed] [Google Scholar]

[pone.0262568.ref015] 15.Pang Z, Nakagami H, Osako MK, Koriyama H, Nakagami F, Tomioka H, et al. Therapeutic vaccine against DPP4 improves glucose metabolism in mice. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(13):E1256–63. doi: 10.1073/pnas.1322009111 ; PubMed Central PMCID: PMC3977240. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0262568.ref016] 16.Kawakami R, Nozato Y, Nakagami H, Ikeda Y, Shimamura M, Yoshida S, et al. Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/kexin type 9 (PCSK9) epitope in mice. PloS one. 2018;13(2):e0191895. doi: 10.1371/journal.pone.0191895 ; PubMed Central PMCID: PMC5811007. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0262568.ref017] 17.Nakagami F, Koriyama H, Nakagami H, Osako MK, Shimamura M, Kyutoku M, et al. Decrease in blood pressure and regression of cardiovascular complications by angiotensin II vaccine in mice. PloS one. 2013;8(3):e60493. doi: 10.1371/journal.pone.0060493 ; PubMed Central PMCID: PMC3609829. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0262568.ref018] 18.Koriyama H, Nakagami H, Nakagami F, Osako MK, Kyutoku M, Shimamura M, et al. Long-Term Reduction of High Blood Pressure by Angiotensin II DNA Vaccine in Spontaneously Hypertensive Rats. Hypertension. 2015;66(1):167–74. doi: 10.1161/HYPERTENSIONAHA.114.04534 . [DOI] [PubMed] [Google Scholar]

[pone.0262568.ref019] 19.Pan Y, Zhou Z, Zhang H, Zhou Y, Li Y, Li C, et al. The ATRQbeta-001 vaccine improves cardiac function and prevents postinfarction cardiac remodeling in mice. Hypertension research: official journal of the Japanese Society of Hypertension. 2019;42(3):329–40. Epub 2018/12/28. doi: 10.1038/s41440-018-0185-3 . [DOI] [PubMed] [Google Scholar]

[pone.0262568.ref020] 20.Watanabe R, Suzuki JI, Wakayama K, Maejima Y, Shimamura M, Koriyama H, et al. A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction. Scientific reports. 2017;7:43920. doi: 10.1038/srep43920 ; PubMed Central PMCID: PMC5339733. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0262568.ref021] 21.Wakayama K, Shimamura M, Suzuki JI, Watanabe R, Koriyama H, Akazawa H, et al. Angiotensin II Peptide Vaccine Protects Ischemic Brain Through Reducing Oxidative Stress. Stroke; a journal of cerebral circulation. 2017;48(5):1362–8. doi: 10.1161/STROKEAHA.116.016269 . [DOI] [PubMed] [Google Scholar]

[pone.0262568.ref022] 22.Nakagami H, Koriyama H, Morishita R. Therapeutic vaccines for hypertension and dyslipidemia. International heart journal. 2014;55(2):96–100. doi: 10.1536/ihj.13-383 . [DOI] [PubMed] [Google Scholar]

[pone.0262568.ref023] 23.Hanaguri J, Yokota H, Watanabe M, Kuo L, Yamagami S, Nagaoka T. Longitudinal stability of retinal blood flow regulation in response to flicker stimulation and systemic hyperoxia in mice assessed with laser speckle flowgraphy. Scientific reports. 2020;10(1):19796. Epub 2020/11/15. doi: 10.1038/s41598-020-75296-y ; PubMed Central PMCID: PMC7666208. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0262568.ref024] 24.Iwase T, Kobayashi M, Yamamoto K, Ra E, Terasaki H. Effects of photocoagulation on ocular blood flow in patients with severe non-proliferative diabetic retinopathy. PloS one. 2017;12(3):e0174427. Epub 2017/03/30. doi: 10.1371/journal.pone.0174427 ; PubMed Central PMCID: PMC5371365. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0262568.ref025] 25.Toto L, Evangelista F, Viggiano P, Erroi E, D’Onofrio G, Libertini D, et al. Changes in Ocular Blood Flow after Ranibizumab Intravitreal Injection for Diabetic Macular Edema Measured Using Laser Speckle Flowgraphy. BioMed research international. 2020;2020:9496242. Epub 2020/02/28. doi: 10.1155/2020/9496242 ; PubMed Central PMCID: PMC7035512. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0262568.ref026] 26.Ichihara A, Sakoda M, Kurauchi-Mito A, Nishiyama A, Itoh H. Involvement of receptor-bound prorenin in development of nephropathy in diabetic db/db mice. Journal of the American Society of Hypertension: JASH. 2008;2(5):332–40. Epub 2008/09/01. doi: 10.1016/j.jash.2008.04.009 . [DOI] [PubMed] [Google Scholar]

[pone.0262568.ref027] 27.Ichihara A, Sakoda M, Kurauchi-Mito A, Narita T, Kinouchi K, Bokuda K, et al. New approaches to blockade of the renin-angiotensin-aldosterone system: characteristics and usefulness of the direct renin inhibitor aliskiren. Journal of pharmacological sciences. 2010;113(4):296–300. Epub 2010/08/03. doi: 10.1254/jphs.10r04fm . [DOI] [PubMed] [Google Scholar]

[pone.0262568.ref028] 28.Titze J, Luft FC. Speculations on salt and the genesis of arterial hypertension. Kidney international. 2017;91(6):1324–35. Epub 2017/05/16. doi: 10.1016/j.kint.2017.02.034 . [DOI] [PubMed] [Google Scholar]

[pone.0262568.ref029] 29.Sheridan PA, Paich HA, Handy J, Karlsson EA, Hudgens MG, Sammon AB, et al. Obesity is associated with impaired immune response to influenza vaccination in humans. Int J Obes (Lond). 2012;36(8):1072–7. Epub 2011/10/26. doi: 10.1038/ijo.2011.208 ; PubMed Central PMCID: PMC3270113. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0262568.ref030] 30.Claycombe K, King LE, Fraker PJ. A role for leptin in sustaining lymphopoiesis and myelopoiesis. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(6):2017–21. Epub 2008/02/06. doi: 10.1073/pnas.0712053105 ; PubMed Central PMCID: PMC2538874. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0262568.ref031] 31.Shamansurova Z, Tan P, Ahmed B, Pepin E, Seda O, Lavoie JL. Adipose tissue (P)RR regulates insulin sensitivity, fat mass and body weight. Mol Metab. 2016;5(10):959–69. doi: 10.1016/j.molmet.2016.08.009 ; PubMed Central PMCID: PMC5034688. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0262568.ref032] 32.Song Y, Nagaoka T, Yoshioka T, Ono S, Wada T, Nakabayashi S, et al. Glial Endothelin-1 Regulates Retinal Blood Flow During Hyperoxia in Cats. Investigative ophthalmology & visual science. 2016;57(11):4962–9. Epub 2016/09/23. doi: 10.1167/iovs.16-19599 . [DOI] [PubMed] [Google Scholar]

[pone.0262568.ref033] 33.Yoshioka T, Nagaoka T, Song Y, Yokota H, Tani T, Yoshida A. Role of neuronal nitric oxide synthase in regulating retinal blood flow during flicker-induced hyperemia in cats. Investigative ophthalmology & visual science. 2015;56(5):3113–20. Epub 2015/03/19. doi: 10.1167/iovs.14-15854 . [DOI] [PubMed] [Google Scholar]

[pone.0262568.ref034] 34.Phipps JA, Dixon MA, Jobling AI, Wang AY, Greferath U, Vessey KA, et al. The renin-angiotensin system and the retinal neurovascular unit: A role in vascular regulation and disease. Experimental eye research. 2019;187:107753. Epub 2019/08/14. doi: 10.1016/j.exer.2019.107753 . [DOI] [PubMed] [Google Scholar]

[pone.0262568.ref035] 35.Arroba AI, Alcalde-Estevez E, Garcia-Ramirez M, Cazzoni D, de la Villa P, Sanchez-Fernandez EM, et al. Modulation of microglia polarization dynamics during diabetic retinopathy in db/db mice. Biochimica et biophysica acta. 2016;1862(9):1663–74. Epub 2016/06/09. doi: 10.1016/j.bbadis.2016.05.024 . [DOI] [PubMed] [Google Scholar]

[pone.0262568.ref036] 36.Shi P, Grobe JL, Desland FA, Zhou G, Shen XZ, Shan Z, et al. Direct pro-inflammatory effects of prorenin on microglia. PloS one. 2014;9(10):e92937. doi: 10.1371/journal.pone.0092937 ; PubMed Central PMCID: PMC4193744. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0262568.ref037] 37.McCarthy CA, Widdop RE, Deliyanti D, Wilkinson-Berka JL. Brain and retinal microglia in health and disease: An unrecognized target of the renin-angiotensin system. Clinical and experimental pharmacology & physiology. 2013;40(8):571–9. Epub 2013/04/23. doi: 10.1111/1440-1681.12099 . [DOI] [PubMed] [Google Scholar]

[pone.0262568.ref038] 38.Kern TS, Barber AJ. Retinal ganglion cells in diabetes. The Journal of physiology. 2008;586(Pt 18):4401–8. doi: 10.1113/jphysiol.2008.156695 ; PubMed Central PMCID: PMC2614025. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0262568.ref039] 39.Vujosevic S, Muraca A, Alkabes M, Villani E, Cavarzeran F, Rossetti L, et al. Early Microvascular and Neural Changes in Patients with Type 1 and Type 2 Diabetes Mellitus without Clinical Signs of Diabetic Retinopathy. Retina. 2019;39(3):435–45. doi: 10.1097/IAE.0000000000001990 . [DOI] [PubMed] [Google Scholar]

[pone.0262568.ref040] 40.Sohn EH, van Dijk HW, Jiao C, Kok PH, Jeong W, Demirkaya N, et al. Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus. Proceedings of the National Academy of Sciences of the United States of America. 2016;113(19):E2655–64. doi: 10.1073/pnas.1522014113 ; PubMed Central PMCID: PMC4868487. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0262568.ref041] 41.Bogdanov P, Corraliza L, Villena JA, Carvalho AR, Garcia-Arumi J, Ramos D, et al. The db/db mouse: a useful model for the study of diabetic retinal neurodegeneration. PloS one. 2014;9(5):e97302. doi: 10.1371/journal.pone.0097302 ; PubMed Central PMCID: PMC4023966. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0262568.ref042] 42.Wilkinson-Berka JL, Heine R, Tan G, Cooper ME, Hatzopoulos KM, Fletcher EL, et al. RILLKKMPSV influences the vasculature, neurons and glia, and (pro)renin receptor expression in the retina. Hypertension. 2010;55(6):1454–60. Epub 2010/04/07. doi: 10.1161/HYPERTENSIONAHA.109.148221 . [DOI] [PubMed] [Google Scholar]

[pone.0262568.ref043] 43.Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61(1):46–54. Epub 2003/07/09. doi: 10.1212/01.wnl.0000073623.84147.a8 . [DOI] [PubMed] [Google Scholar]

[pone.0262568.ref044] 44.Horio N, Clermont AC, Abiko A, Abiko T, Shoelson BD, Bursell SE, et al. Angiotensin AT(1) receptor antagonism normalizes retinal blood flow and acetylcholine-induced vasodilatation in normotensive diabetic rats. Diabetologia. 2004;47(1):113–23. Epub 2003/11/18. doi: 10.1007/s00125-003-1262-x . [DOI] [PubMed] [Google Scholar]

[pone.0262568.ref045] 45.Mori F, Hikichi T, Nagaoka T, Takahashi J, Kitaya N, Yoshida A. Inhibitory effect of losartan, an AT1 angiotensin II receptor antagonist, on increased leucocyte entrapment in retinal microcirculation of diabetic rats. The British journal of ophthalmology. 2002;86(10):1172–4. Epub 2002/09/18. doi: 10.1136/bjo.86.10.1172 ; PubMed Central PMCID: PMC1771309. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0262568.ref046] 46.Otani A, Takagi H, Oh H, Suzuma K, Matsumura M, Ikeda E, et al. Angiotensin II-stimulated vascular endothelial growth factor expression in bovine retinal pericytes. Investigative ophthalmology & visual science. 2000;41(5):1192–9. Epub 2001/02/07. . [PubMed] [Google Scholar]

[pone.0262568.ref047] 47.Zeng Y, Cao D, Yu H, Yang D, Zhuang X, Hu Y, et al. Early retinal neurovascular impairment in patients with diabetes without clinically detectable retinopathy. The British journal of ophthalmology. 2019. doi: 10.1136/bjophthalmol-2018-313582 [DOI] [PubMed] [Google Scholar]

[pone.0262568.ref048] 48.Saavedra JM. Angiotensin II AT(1) receptor blockers ameliorate inflammatory stress: a beneficial effect for the treatment of brain disorders. Cellular and molecular neurobiology. 2012;32(5):667–81. Epub 2011/09/23. doi: 10.1007/s10571-011-9754-6 ; PubMed Central PMCID: PMC3302944. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0262568.ref049] 49.Dong YF, Kataoka K, Tokutomi Y, Nako H, Nakamura T, Toyama K, et al. Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer’s disease. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2011;25(9):2911–20. Epub 2011/05/20. doi: 10.1096/fj.11-182873 . [DOI] [PubMed] [Google Scholar]

[pone.0262568.ref050] 50.Benicky J, Sanchez-Lemus E, Honda M, Pang T, Orecna M, Wang J, et al. Angiotensin II AT1 receptor blockade ameliorates brain inflammation. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. 2011;36(4):857–70. Epub 2010/12/15. doi: 10.1038/npp.2010.225 ; PubMed Central PMCID: PMC3055735. [DOI] [PMC free article] [PubMed] [Google Scholar]

[pone.0262568.ref051] 51.Miyoshi M, Miyano K, Moriyama N, Taniguchi M, Watanabe T. Angiotensin type 1 receptor antagonist inhibits lipopolysaccharide-induced stimulation of rat microglial cells by suppressing nuclear factor kappaB and activator protein-1 activation. The European journal of neuroscience. 2008;27(2):343–51. Epub 2008/01/15. doi: 10.1111/j.1460-9568.2007.06014.x . [DOI] [PubMed] [Google Scholar]

[pone.0262568.ref052] 52.Zhu T, Miller AG, Deliyanti D, Berka DR, Agrotis A, Campbell DJ, et al. Prorenin stimulates a pro-angiogenic and pro-inflammatory response in retinal endothelial cells and an M1 phenotype in retinal microglia. Clinical and experimental pharmacology & physiology. 2015;42(5):537–48. doi: 10.1111/1440-1681.12376 . [DOI] [PubMed] [Google Scholar]

[pone.0262568.ref053] 53.Renner S, Blutke A, Clauss S, Deeg CA, Kemter E, Merkus D, et al. Porcine models for studying complications and organ crosstalk in diabetes mellitus. Cell and tissue research. 2020;380(2):341–78. Epub 2020/01/15. doi: 10.1007/s00441-019-03158-9 . [DOI] [PubMed] [Google Scholar]

PERMALINK

Effect of prorenin peptide vaccine on the early phase of diabetic retinopathy in a murine model of type 2 diabetes

Harumasa Yokota

Hiroki Hayashi

Junya Hanaguri

Satoru Yamagami

Akifumi Kushiyama

Hironori Nakagami

Taiji Nagaoka

Roles

Abstract

Introduction

Materials and methods

Animals

Vaccine preparation

Fig 1. Planning of optimization of prorenin peptide vaccine.

Vaccination of C57BL/6 mice to determine the antigen for prorenin peptide vaccine

Vaccination to test the effect of prorenin peptide vaccine in db/db mice as a T2D model

Fig 3. Immunization with a prorenin peptide vaccine.

Measurement of retinal blood flow

Induction of hyperoxia

Flicker light stimulation

Electroretinogram in db/db mice

Antibody titer measurement

ELISA for measurement of prorenin plus renin and angiotensin I

Western blotting

Immunohistochemistry

Enzyme-linked immunosorbent spot assay

Statistical analysis

Results

Determination of the antigen for developing a prorenin peptide vaccine

Fig 2.

Antibody titer, body weight, blood glucose, blood pressure, renin activity, and (pro)renin receptor expression in db/m and db/db mice after injection of VP

Protective effect of VP on glial function (retinal blood flow response to systemic hyperoxia and flicker light stimulation)

Fig 4. Effect of prorenin peptide vaccine (VP) on glial dysfunction.

Fig 5. Immunohistochemical analysis of gliosis and microglia activation.

Protective effect of VP on retinal neuronal function in db/db mice

Fig 6. Electroretinography at 20 weeks of age in diabetic (db/db) and non-diabetic (db/m) mice after injection of prorenin peptide vaccine (VP).

Inhibitory effect of VP on VEGF expression and vascular permeability

Fig 7. Immunohistochemical analysis of vascular leakage in the retina of mice at 24 weeks of age.

T-cell activation after inoculation with VP

Fig 8. Enzyme-linked immune absorbent spot assay with splenocytes (1×106 cells) from C57BL/6 mice immunized with prorenin peptide vaccine (VP).

Comparison of VP with angiotensin II peptide vaccine (VA)

Fig 9. Comparison of neuroprotection by angiotensin II peptide vaccine (VA) and prorenin peptide vaccine (VP) in the retina of db/db mice.

Discussion

Conclusion

Supporting information

Acknowledgments

Data Availability

Funding Statement

References

Decision Letter 0

Alfred S Lewin

Roles

Author response to Decision Letter 0

Decision Letter 1

Alfred S Lewin

Roles

Acceptance letter

Alfred S Lewin

Roles

Associated Data

Supplementary Materials

Data Availability Statement

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases

Antibody titer, body weight, blood glucose, blood pressure, renin activity, and (pro)renin receptor expression in db/m and db/db mice after injection of V_P

Protective effect of V_P on glial function (retinal blood flow response to systemic hyperoxia and flicker light stimulation)

Fig 4. Effect of prorenin peptide vaccine (V_P) on glial dysfunction.

Protective effect of V_P on retinal neuronal function in db/db mice

Fig 6. Electroretinography at 20 weeks of age in diabetic (db/db) and non-diabetic (db/m) mice after injection of prorenin peptide vaccine (V_P).

Inhibitory effect of V_P on VEGF expression and vascular permeability

T-cell activation after inoculation with V_P

Fig 8. Enzyme-linked immune absorbent spot assay with splenocytes (1×10⁶ cells) from C57BL/6 mice immunized with prorenin peptide vaccine (V_P).

Comparison of V_P with angiotensin II peptide vaccine (V_A)

Fig 9. Comparison of neuroprotection by angiotensin II peptide vaccine (V_A) and prorenin peptide vaccine (V_P) in the retina of db/db mice.